Ciprofloxacin and levofloxacin reitance among methicillin-enitive taphylococcu aureu iolate from keratiti and conjunctiviti

Purpoe The majority of taphylococcuaureu iolated from ocular infection are methicillin enitive (MA). Fluoroquinolone reitance among methicillin- reitant taphylococcuaureu i well known but not among MA. In thi tudy we invetigate the emergence of fluoroquinolone (ciprofloxacin, levofloxacin) reitance among methicillin-enitive taphylococcuaureu iolate from keratiti and conjunctiviti. Deign Cro-ectional tudy. Method Minimal inhibitory concentration uceptibility profile for 1230 . aureu iolate from keratiti and conjunctiviti were analyzed. Hitorical and current rate of emerging fluoroquinolone reitance for methicillin-reitant (MRA) and methicillin-enitive iolate (MA) were evaluated. enitivity pattern for vancomycin and gentamicin were alo documented. Reult Ciprofloxacin reitance among corneal and conjunctival . aureu iolate during the firt 6 year after it introduction (baeline) (1990–1995) wa 8% and ranged from 3% to 11%. The rate for the mot recent 6 year (current) (1996–2001) wa 20.7%. Baeline ciprofloxacin reitance for MA iolate wa 2% v 55.8% for MRA. The current reitance rate for MA i 5% v 83.7% for MRA. The general reitance rate from January 2000 to December 2001 for levofloxacin wa 25.5% v 33.2% for ciprofloxacin (P = .13). The levofloxacin-reitance rate for MA wa 4.7% v 11.9% for ciprofloxacin (P = .05). In MRA iolate, a higher reitance rate wa found for ciprofloxacin (95.7%) v levofloxacin (82.1%) (P = .04). No reitance for vancomycin wa documented for any of the . aureu iolate. Gentamicin uceptibility for MA wa 99% and MRA wa 86%. Concluion Ciprofloxacin and levofloxacin reitance among methicillin-enitive . aureu corneal and conjunctival iolate i increaing. Thi i of concern becaue it narrow treatment choice for the management of thee common ocular infection.